 Ritonavir
"Ritonavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV.
| Descriptor ID |
D019438
|
| MeSH Number(s) |
D02.886.675.653 D03.383.129.708.653
|
| Concept/Terms |
ABT 538- ABT 538
- 538, ABT
- ABT-538
- ABT538
|
Below are MeSH descriptors whose meaning is more general than "Ritonavir".
Below are MeSH descriptors whose meaning is more specific than "Ritonavir".
This graph shows the total number of publications written about "Ritonavir" by people in this website by year, and whether "Ritonavir" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ritonavir" by people in Profiles.
-
Reyskens KM, Fisher TL, Schisler JC, O'Connor WG, Rogers AB, Willis MS, Planesse C, Boyer F, Rondeau P, Bourdon E, Essop MF. Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir). PLoS One. 2013; 8(9):e73347.
-
Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, Yogev R, Capparelli EV, Chadwick EG. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS. 2012 Jul 31; 26(12):1483-90.
-
Azzoni L, Foulkes AS, Firnhaber C, Yin X, Xiang ZQ, Li Y, Stevens W, Gross R, Ertl HC, Sanne I, Montaner LJ. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
-
Firnhaber C, Azzoni L, Foulkes AS, Gross R, Yin X, Van Amsterdam D, Schulze D, Glencross DK, Stevens W, Hunt G, Morris L, Fox L, Sanne I, Montaner LJ. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450.
-
Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008 Jul-Sep; 10(3):131-42.
-
Prot M, Heripret L, Cardot-Leccia N, Perrin C, Aouadi M, Lavrut T, Garraffo R, Dellamonica P, Durant J, Le Marchand-Brustel Y, Binétruy B. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother. 2006 Dec; 50(12):3998-4004.
-
Oki T, Usami Y, Nakai M, Sagisaka M, Ito H, Nagaoka K, Mamiya N, Yamanaka K, Utsumi M, Kaneda T. Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers. Biol Pharm Bull. 2004 Feb; 27(2):261-5.
-
Usami Y, Oki T, Nakai M, Sagisaka M, Kaneda T. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz. Chem Pharm Bull (Tokyo). 2003 Jun; 51(6):715-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|